Navigation Links
Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Date:9/10/2007

-R7128 Demonstrates Safety and Tolerability with No Clinically Significant

Adverse Events-

-Conference Call Scheduled for 8:30AM (ET) Today-

PRINCETON, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) is presenting safety, tolerability, pharmacokinetic and food effect data following single ascending doses of R7128 at the 14th International Symposium on Hepatitis C Virus and Related Viruses being held from September 9-13, 2007 in Glasgow, Scotland. R7128 is a prodrug of PSI- 6130, an oral cytidine nucleoside analog polymerase inhibitor of hepatitis C virus (HCV) that is being developed through Pharmasset's collaboration with Roche. The poster presentation from the conference is available in the "Events and Presentations" section of the Investor Center on Pharmasset's website at http://www.pharmasset.com.

The Phase 1 single ascending dose study of R7128 was designed to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of this study was to explore the effect of food on the pharmacokinetics of R7128. Single oral doses of R7128 were administered to 46 healthy volunteers in five sequential dose groups (500 mg, 1500 mg, 4500 mg, 6000 mg, and 9000 mg) and one food effect group (1500 mg). There were 8 subjects per sequential dose group (6 active, 2 placebo) and 6 subjects in the food effect group (all active).

Nineteen adverse events (AEs) were reported during the study, including headache, sunburn, sore throat and nasal congestion. All AEs were mild to moderate, none were related to dose and no
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... For the first time, cardiac surgeons, medical ... the SynCardia temporary Total Artificial Heart in a peer ... the Journal of Visualized Experiments website. ... the SynCardia Total Artificial Heart implantation   goo.gl/2OZyKW ... the SynCardia Total Artificial Heart," a July 18, 2014 ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... options and research directions , , WASHINGTON, June ... therapeutic option for many patients with interstitial cystitis (IC). IC ... 8 million women and 1.5 million men in the United ... noticed a correlation between allergies and IC. Recently, a urologist ...
... Families of Spinal Muscular Atrophy has just released details ... funded therapeutic pipeline. , , Families of SMA ... Quinazolines to boost gene expression; 2) Tetracyclines at Paratek ... replacement program at California Stem Cell and UCI. ...
Cached Medicine Technology:Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 2Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 3Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 4Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 2Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 3
(Date:7/31/2014)... Mountain View, Calif. and Las Vegas, Nevada (PRWEB) July ... a partnership with LaunchKey to provide next generation authentication ... a simple and secure way to utilize hardware protected ... an enormous problem in the Internet's reliance on password-based ... of hacks and global data breaches taking place around ...
(Date:7/31/2014)... 2014 The Beryl Institute announces three ... and four new members of its Patient ... the global community of practice and premier thought leader ... Executive board members are industry leaders who advise on ... insight into market and industry trends. The advisory board ...
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... HealthDay Reporter , WEDNESDAY, July 30, ... isn,t warranted based on current evidence, a team of ... compete with regular cigarettes might cut tobacco-related deaths and ... on the use and safety of the nicotine-emitting devices. ... a potential for smokers to reduce their health risks ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... company has launched a new online reputation management ... help individuals as well as organizations get rid ... service is the result of extensive research. ReputationChief.Com ... design a service for those who are struggling ...
Breaking Medicine News(10 mins):Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 2Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 3Health News:ReputationChief.Com Announces a New Online Reputation Management Service 2
... , MONDAY, April 11 (HealthDay News) -- Progressive resistance ... to function better in daily life, researchers say. A ... review of available evidence and concluded that an adult can ... and increase their overall strength by 25 percent to 30 ...
... Ore. An Oregon Health & Science University researcher has ... prevent rejection in organ transplant patients helped treat a rare ... cure and, until now, no known treatment. The clinical ... first randomized, controlled study designed to develop a therapy for ...
... By Steven Reinberg HealthDay Reporter , MONDAY, April ... engines cuts emissions of heart-harmful microscopic particles by 98 percent, ... new study suggests. The very tiny particles found in ... heart disease caused by air pollution, but "if we use ...
... treatment for osteoporosis has often been associated with serious ... Sweden, have now, in mice, found a way of ... that only the skeleton is acted on, current research ... in the respected journal PNAS (Proceedings of the National ...
... A study appearing in the journal Investigational New Drugs ... that two new small molecule inhibitors are showing promise ... common malignant bone tumor, osteosarcoma. These small molecule inhibitors ... spice may serve as a new, non-toxic treatment ...
... Nearly all patients with advanced cancer experience severe pain, and ... regardless of the type or stage of the disease. Pain ... new study, led by Wayne State University,s College of Nursing ... Cancer Institute of the National Institutes of Health, aims to ...
Cached Medicine News:Health News:Progressive Weight Training Can Boost Seniors' Strength 2Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Emissions Trap Cuts Harmful Diesel Pollution 2Health News:Emissions Trap Cuts Harmful Diesel Pollution 3Health News:New study finds compounds show promise in blocking STAT3 signaling as treatment for osteosarcoma 2Health News:Wayne State leads study to improve management of cancer pain in African Americans 2
A One Piece Support Garment - any length or size...
Body Suit w/Bra torso, Front Closure...
Gynecomastia Vest...
Ideal for breast compression and contouring breast cups....
Medicine Products: